TMO
Thermo Fisher Scientific Inc. · Healthcare · Medical - Diagnostics & Research
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 875.63K | $561.43M | n/a | −3 |
| Q2 2026 | 189 | +3 | 258.75M | $130.52B | +5 | −3 |
| Q1 2026 | 190 | +2 | 255.88M | $126.62B | +7 | −6 |
| Q4 2025 | 187 | +3 | 274.75M | $159.19B | +4 | n/a |
| Q3 2025 | 29 | -1 | 154.46M | $74.90B | +1 | −3 |
| Q2 2025 | 28 | +3 | 123.95M | $50.25B | +3 | n/a |
| Q1 2025 | 22 | -2 | 60.64M | $30.17B | n/a | −2 |
| Q4 2024 | 24 | +2 | 61.50M | $31.99B | +2 | n/a |
| Q3 2024 | 21 | -2 | 44.46M | $27.48B | n/a | −2 |
| Q2 2024 | 23 | n/a | 44.78M | $24.75B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 9.93M | n/a | $5.49B | 0.7% | n/c | 1 | SEC ↗ ×2 |
| 2 | Capital World Investors ✦ | 9.52M | n/a | $5.26B | 0.9% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passief) | 7.53M | n/a | $4.15B | 0.4% | n/c | 1 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passief) | 5.57M | n/a | $3.08B | 0.5% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 3.03M | n/a | $1.67B | 0.3% | n/c | 1 | SEC ↗ ×8 |
| 6 | PRIMECAP Management ✦ | 2.67M | n/a | $1.47B | 1.1% | n/c | 1 | SEC ↗ |
| 7 | Fisher Asset Management ✦ | 2.57M | n/a | $1.42B | 0.6% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 982.69K | n/a | $543.43M | 0.5% | n/c | 1 | SEC ↗ ×2 |
| 9 | Baillie Gifford ✦ | 621.52K | n/a | $343.70M | 0.3% | n/c | 1 | SEC ↗ ×4 |
| 10 | Millennium Management ✦ | 565.42K | n/a | $312.68M | 0.3% | n/c | 1 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 427.81K | n/a | $236.58M | 0.6% | n/c | 1 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 351.91K | n/a | $194.61M | 0.4% | n/c | 1 | SEC ↗ |
| 13 | Point72 Asset Management ✦ | 336.54K | n/a | $186.10M | 0.6% | n/c | 1 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 235.85K | n/a | $130.42M | 0.2% | n/c | 1 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 201.26K | n/a | $111.30M | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 16 | AQR Capital Management ✦ | 98.15K | n/a | $54.28M | 0.1% | n/c | 1 | SEC ↗ ×4 |
| 17 | Bridgewater Associates ✦ | 33.73K | n/a | $18.65M | 0.1% | n/c | 1 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 29.95K | n/a | $16.56M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Markel Group ✦ | 29.40K | n/a | $16.26M | 0.2% | n/c | 1 | SEC ↗ |
| 20 | Dodge & Cox ✦ | 26.79K | n/a | $14.82M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 21.28K | n/a | $11.77M | 0.2% | n/c | 1 | SEC ↗ |
| 22 | GAMCO Investors ✦ | 4.29K | n/a | $2.37M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Marshall Wace ✦ | 700 | n/a | $387,100 | 0.0% | n/c | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1 houders, 24.30K aandelen, $11,944 gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 3.73K aand · $2.29M
Officer · 400 aand · $245,752
Officer, Director · 62 aand · $38,982
Officer, Director · 33 aand · $20,677
Officer, Director · 101 aand · $63,166
Officer, Director · 79 aand · $49,613
Officer, Director · 2.15K aand · $1.35M
Officer, Director · 1.79K aand · $1.12M
Officer, Director · 3.01K aand · $1.89M
Officer, Director · 2.73K aand · $1.71M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie